Authors: Lubomir Bodnar Gabriel Wcislo Anna Nasilowska Katarzyna SzarlejWcislo Agnieszka GasowskaBodnar Marta Smoter Cezary Szczylik
Publish Date: 2008/11/26
Volume: 135, Issue: 6, Pages: 815-
Abstract
Between January 2004 and June 2007 25 cases of HPOC were treated with topotecan as 30min infusion at the dose of 15 mg/m2 through 5 consecutive days every 21 days We assessed toxicity profile using NCI CTC and the response was measured according to RECIST and CA125 criteria described by RustinHeavily pretreated ovarian cancer received at least two cycles of topotecan median 6 range 2–6 with prior chemotherapy lines median 3 range 3–7 In 20 HPOC who met RECIST criteria results were as follows PR 6/20 30 NC 7/20 35 PD 7/20 35 Biochemical response was noted in 20 patients having 15 3/20 of 75 and 20 4/20 of 50 decline of CA125 Time to progression was median 6 months 95 CI 406–618 and overall survival was median 9 months 95 CI 869–1627 In multivariate analysis primary optimal debulking and response to primary chemotherapy HR = 024 95 CI 008–069 P = 00084 HR = 038 95 CI 014–098 P = 00448 respectively were independent prognostic factors when assessed in relation to salvage therapy with topotecan We did not observe difference in side effects after topotecan treatment among patients in relation to the higher number of previously used chemotherapy line 3 vs 3
Keywords: